CHICAGO, Oct 25 (Reuters) - Cardiovascular device maker Edwards Lifesciences Corp. (EW.N: Quote, Profile, Research) on Tuesday said it still expects to resume by year-end an early-stage clinical trial for an alternative to open-heart surgery to replace the aortic valve.
